1,248
Views
16
CrossRef citations to date
0
Altmetric
Review Articles

Silver, copper and copper oxide nanoparticles in the fight against human viruses: progress and perspectives

, , , ORCID Icon, ORCID Icon, & show all
Pages 431-449 | Received 21 Nov 2020, Accepted 07 May 2021, Published online: 07 Jul 2021
 

Abstract

The rapid development of nanomedicine has created a high demand for silver, copper and copper oxide nanoparticles. Due to their high reactivity and potent antimicrobial activity, silver and copper-based nanomaterials have been playing an important role in the search for new alternatives for the treatment of several issues of concern, such as pathologies caused by bacteria and viruses. Viral diseases are a significant and constant threat to public health. The most recent example is the pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In this context, the object of the present review is to highlight recent progress in the biomedical uses of these metal nanoparticles for the treatment and prevention of human viral infections. We discuss the antiviral activity of AgNPs and Cu-based NPs, including their actions against SARS-CoV-2. We also discuss the toxicity, biodistribution and excretion of AgNPs and CuNPs, along with their uses in medical devices or on inert surfaces to avoid viral dissemination by fomites. The challenges and limitations of the biomedical use of these nanoparticles are presented.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Additional information

Funding

This research was funded by REDES-ANID 180003, Universidad de La Frontera DI21-1004, CONICYT/FAPESP 2018/08194-2, FAPESP [2018/08194-2, 2018/02832-7], CNPq [404815/2018-9, 313117/2019-5]. This study was financed in part by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior – Brasil (CAPES) – Finance Code 001 and ANID/FONDAP/15130015.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.